"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

The latest health news includes Siemens proposing Mark Schneider for supervisory board head, discussions on climate change's impact on health, rising malaria cases, a new lawsuit against food ...

The partnership between Ro and Eli Lilly (LLY) to streamline access to Lilly’s GLP-1 Zepbound single-dose vials for Ro patients with obesity is ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Eli Lily continues to dominate the weight loss market, willing to crush any competitor that threatens its dominance.

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Eli Lilly (NYSE:LLY) plans to streamline patient access to its weight-loss drug Zepbound by offering single-dose vials ...

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

Eli Lilly has partnered with direct-to-consumer health-care startup Ro to offer more affordable single-dose vials of its ...

BofA analyst Allen Lutz notes Ro Health, a direct competitor to Hims & Hers (HIMS), announced that the company is working with Eli Lilly ...

AnaptysBio said on Wednesday it would end the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.